Junjie Li, MD, associate chief physician at Fudan University Shanghai Cancer Center, Shanghai, China, talks with Saba Shaikh, MD, about the HER2-directed antibody-drug conjugate SHR-A1811 in the neoadjuvant treatment of HER2-positive early breast cancer.
▷ Estimated Read Time:
1–2 minutes
SABCS Snippets: SHR-A1811 in the Neoadjuvant Treatment of HER2-positive Early Breast Cancer
Join the global breast cancer community for four days of research spanning experimental biology, etiology, translational science, prevention, diagnosis and treatment, December 8-11 in San Antonio, Texas.
Share: